Interleukin-2 data

CHIR (Emeryville, Calif.) and Merck & Co. (West Point, Penn.) reported that some patients have shown an additional increase in CD4 T cell counts when Merck's MK-639 HIV protease inhibitor is added to treatment with IL-2.

While IL-2 alone can produce substantial increases in CD4 counts, patients with low CD4 counts don't respond. Patients enrolled in this ongoing, open-label trial started with CD4 counts below 300. ...